Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): Observational study protocol

BMJ Open

Volumn 5, Issue 7, 2015, Pages

  Soria, Carlos A ^a   Remedi, Carolina ^a   Núñez, Daniel A ^b   D'Alessio, Luciana ^a   Roldán, Emilio J A ^b  

^a Institute of Biosciences Henri Laborit   (Argentina)

^b Gador SA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT;

ALLOSTASIS; ALLOSTATIC LOAD; ANXIETY; ANXIETY DISORDER; ARTICLE; CHRONIC STRESS; CLINICAL PROTOCOL; COGNITION; HAMILTON ANXIETY SCALE; HUMAN; NEUROCHEMISTRY; NEUROCOGNITION; NEUROSIS; OBSERVATIONAL STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; STATE TRAIT ANXIETY INVENTORY; STUDY DESIGN; TRANQUILIZING ACTIVITY; ADULT; AGED; ANXIETY DISORDERS; ARGENTINA; CLINICAL TRIAL; FEMALE; MALE; MENTAL STRESS; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ALLOSTASIS; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; ARGENTINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84937232291     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007231     Document Type: Article

References (84)

1. Lahey BB. Public health significance of neuroticism. Am Psychol 2009; 4:241-56.
2. Garcia-Banda G., Chellew K, Fornes J., et al. Neuroticism and cortisol: pinning down an expected effect. Int J Psychophysiol 2014; 91:132-8.
3. Plag J, Gaudlitz K, Schumacher S., et al. Effect of combined cognitive-behavioural therapy and endurance training on cortisol and salivary alpha-amylase in panic disorder. J Psychiatr Res 2014; 58:12-19.
4. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci 1998; 1:33-44.
5. McEwen BS. Stressed or stressed out: what is the difference? J Psychiatry Neurosci 2005; 30:315-18.
6. McEwen BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000; 48:721-31.
7. Karatsoreos IN, McEwen BS Resilience and vulnerability: a neurobiological perspective. F1000Prime Rep 2013; 5:13.
8. Brotman DJ, Golden SH, Wittstein IS The cardiovascular toll of stress. Lancet 2007; 370:1089-100.
9. McEwen BS, Gianaros PJ Stress- and allostasis-induced brain plasticity. Annu Rev Med 2011; 62:431-45.
10. Crimmins EM, Johnston M, Hayward M., et al. Age differences in allostatic load: an index of physiological dysregulation. Exp Gerontol 2003; 38:731-4.
11. Maidana P, Bruno OD Medición de cortisol y sus fracciones: Concepto de fracción activa. Medicina 2013; 73:579-84.
12. Schumacher S, Gaudlitz K, Plag J., et al. Who is stressed? A pilot study of salivary cortisol and alpha-amylase concentrations in agoraphobic patients and their novice therapists undergoing in vivo exposure. Psychoneuroendocrinology 2014; 49:280-9.
13. Heaney JLJ, Phillips AC, Carroll D. Ageing, depression, anxiety, social support and the diurnal rhythm and awakening response of salivary cortisol. Int J Psychophysiol. 2010; 78:201-8.
14. Davis M, Walker DL, Lee Y. Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos Trans R Soc Lond B Biol Sci 1997; 352:1675-87.
15. Sanford LD, Nassar P, Ross R.J., et al. Prolactin microinjections into the amygdalar central nucleus lead to decreased NREM sleep. Sleep Res Online 1998; 1:109-13.
16. Wedekind D, Bandelow B, Broocks A., et al. Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm 2000; 107:831-7.
17. Mantella RC, Butters M, Amico J., et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 2008; 33:773-81.
18. Hek K, Direk N, Newson R.S., et al. Anxiety disorders and salivary cortisol levels in older adults: a population-based study. Psychoneuroendocrinology 2013; 38:300-5.
19. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann N Y Acad Sci 2006; 1071:137-66.
20. Vinkers CH, Joëls M, Milaneschi Y., et al. Stress exposure across the life span cumulatively increases depression risk and is moderated by neuroticism. Depress Anxiety 2014; 31:737-45.
21. Suls J, Martin RJ The daily life of the garden-variety neurotic: reactivity, stressor exposure, mood spillover, and maladaptive coping. J Pers 2005; 73:1485-509.
22. Yamada S, Yamauchi K, Yajima J., et al. Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders. Psychiatry Res 2000; 93:217-23.
23. Karege F, Bovier P, Gaillard J., et al. The heterogeneity of 3 - met hoxy-4-hydr oxy-phenylglycol levels among depressed patients. Acta Psychiatr Sacand 1989; 80:499-504.
24. Muscettola G, Potter WZ, Pickar D, et al Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings. Arch Gen Psychiatry 1984; 41: 337-42.
25. Seeman T, Epel E, Gruenewald T., et al. Socio-economic differentials in peripheral biology: cumulative allostatic load. Ann N Y Acad Sci 2010; 1186:223-39.
26. Sheline YI, Wang PW, Gado M.H., et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93:3908-13.
27. Sheline YI, Sanghavi M, Mintun M., et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19:5034-43.
28. Bergson C, Mrzljak L, Smiley F., et al. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 1995; 15:7821-36.
29. Hains AB, Vu MAT, Maciejewski PK, et al Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Proc Natl Acad Sci USA 2009; 106:17957-62.
30. Danese A, McEwen BS Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav 2012; 106:29-39.
31. Braunstein-Bercovitz H., Dimentman-Ashkenazi I, Lubow RE. Stress affects the selection of relevant from irrelevant stimuli. Emotion 2001; 1:182-92.
32. al'Absi M, Hugdahl K, Lovallo WR. Adrenocortical stress responses and altered working memory performance. Psychophysiology 2002; 39:95-9.
33. Uhlenhuth EH, Starcevic V, Qualls C., et al. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder. Depress Anxiety 2008; 25:E18-26.
34. Hoge EA, Ivkovic A, Fricchione GL Generalized anxiety disorder: diagnosis and treatment. BMJ 2012; 345:e7500.
35. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44:151-347.
36. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012; 345:e6231.
37. Barker MJ, Greenwood KM, Jackson M, et al Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004; 19:437-54.
38. Wein AJ. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. J Urol 2013; 190:2168.
39. Curtis GC, Abelson JL, Gold PW Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 1997; 41:76-85.
40. Abelson JL, Curtis GC, Cameron OG Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res 1996; 30:79-93.
41. Fries E, Hellhammer DH, Hellhammer J. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. Psychoneuroendocrinology 2006; 31:1278-88.
42. Pomara N, Willoughby LM, Ritchie J.C., et al. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology 2005; 182:414-19.
43. Manthey L, Giltay EJ, van Veen T, et al. Long-term benzodiazepine use and salivary cortisol: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychopharmacol 2010; 30:160-8.
44. Laakmann G, Wittmann M, Gugath M., et al. Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology 1984; 84:66-70.
45. Pomara N, Willoughby LM, Ritchie J.C., et al. Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. Neuropsychopharmacology 2004; 29:605-11.
46. Coplan JD, Papp LA, Pine D, et al Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 1997; 54:643-8.
47. Zemishlany Z, McQueeney R, Gabriel S.M., et al. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. Neuropsychobiology 1990; 23:124-8.
48. Kroboth PD, Salek FS, Stone R.A., et al. Alprazolam increases dehydroepiandrosterone concentrations. J Clin Psychopharmacol 1999; 19:114-24.
49. Soria CA, Remedi C, Muñóz MS, et al. Translational assessment of alprazolam on MHPG, cortisol and cognitive function in patients with neuroticism, allostatic load and anxiety disorders. Int J Neuropsychopharmacol 2010; 13:268.
50. Möhler H. Role of GABAA receptors in cognition. Biochem Soc Trans 2009; 37:1328-33.
51. Maubach K. GABA(A) receptor subtype selective cognition enhancers. Curr Drug Targets-CNS Neurol Disord 2003; 2:233-9.
52. Vasa RA, Pine DS, Masten C.L., et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology 2009; 204:445-55.
53. Wong M, Kling MA, Munson P.J., et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Clin Res 2000; 97:325-30.
54. Juster R, Mcewen BS, Lupien SJ Neuroscience and Biobehavioral Reviews Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev 2010; 35:2-16.
55. Yaffe K, Boustani M. Benzodiazepines and risk of Alzheimer's disease. BMJ 2014; 349:g5312.
56. Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 1986; 23:179-213.
57. Hanlon JT, Horner RD, Schmader K.E., et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 1998; 64:684-92.
58. Paterniti S, Dufouil CAA. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002; 22:285-93.
59. Gallacher J, Elwood P, Pickering J., et al. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Heal 2012; 66:869-73.
60. Wu CS, Wang SC, Chang I.S., et al. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009; 17:614-20.
61. Johansson L, Duberstein PR, Hällström T. Midlife personality and risk of Alzheimer disease and distress. Neurology 2015; 84:1526-632.
62. Allard J, Artero S, Ritchie K. Consumption of psychotropic medication in the elderly: a re-evaluation of its effect on cognitive performance. Int J Geriatr Psychiatry 2004; 18:874-8.
63. Boeuf-Cazou O., Bongue B, Ansiau D., et al. Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort. Eur J Clin Pharmacol 2011; 67:1045-52.
64. Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12:14-17.
65. Sultan S, Gebara EG, Moullec K, et al D-serine increases adult hippocampal neurogenesis. Front Neurosci 2013; 7:155.
66. Ellinwood EH, Heatherly DG, Nikaido A.M., et al. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology (Berl) 1985; 86: 392-9.
67. Tan KR, Rudolph U, Lüscher C. Hooke don benzodiazepines: GABAA receptor subtypes and addiction. Trends in Neurosci 2011; 34:188-97.
68. Norton PJ, Price EC A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007; 195:521-31.
69. Fleishaker JC, Garzone PD, Chambers J.H., et al. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Psychopharmacology 1995; 120:169-76.
70. Hamilton M. Hamilton anxiety rating scale (HAM-A). Br J Med Psychol 1959; 32:50-5.
71. Costa PT, McCrae RR Inventario de Personalidad NEO revisado (NEO PI-R) e Inventario NEO reducido de Cinco Factores (NEO-FFI). Manual Professional. Madrid: TEA Ediciones, 1999.
72. Folstein MF. Mini-Mental State: a practical method for grading the mental state of patients for the clinician. Psychiatr Res 1975; 12:189-98.
73. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th edn. Washington DC: American Psychiatric Association, 1994.
74. Laux L, Glanzmann P, Schaffner P., et al. State-Trait-Angst-Inventar STAI. Weinheim: Beltz, 1981.
75. WHO. Mental disorders glossary and guide to their classification in accordance with the ninth revision of the international classification of diseases. Geneva: WHO, 1978.
76. Lingjaerde O, Ahlfors UG, Bech P, et al The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
77. Conners K, Jeff JL ADHD in adults and children: The latest assessment and treatment strategies. Kansas City, MO: Compact Clinicals, 1999.
78. Wechsler D. Manual, Wechsler Adult Intelligence Scale - revised. Psychol Corp New York. 1981.
79. Wechsler D. WMS-III Administration and Scoring Manual. San Antonio, TX:The Psychological Corporation. Harcourt Brace & Co., 1997.
80. Elwood ER. The Wechsler Memory Scale - Revised: Psychometric characteristics and clinical application. Neuropsychology Review 1991; 2:179-201.
81. Regard M, Strauss E, Knapp P. Childrens' production on verbal and non-verbal fluency tasks. Percept Mot Ski 1982; 55:839-44.
82. Taylor LB. Localization of cerebral lesions by psychological testing. Clin Neurosurg 1969; 16:269-87.
83. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18:643-62.
84. Augustovskia FA, Lewina G, García Elorriob E. The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. J Clin Epidemiol 2008; 61:1279-84.